Document:

EXHIBIT 10.1

                             DATED 5th November 1998

                           INTRACELL VACCINES LIMITED
                                       and
                            UNIVERSITY OF BIRMINGHAM

                                     LICENCE
                                    AGREEMENT

                                       30
<PAGE>

                                LICENCE AGREEMENT

THIS LICENCE is made the 5th day of November one thousandnine hundred and ninety
eight

BETWEEN:             Intracell Vaccines Ltd,
                     1 Sydney Mount, Circular Road,
                     Douglas, Isle of Man IM1 3DB (hereinafter referred to as
                     "the Licensee")

AND:                 UNIVERSITY OF BIRMINGHAM,
                     Edgbaston,
                     Birmingham B15 2TT (hereinafter  referred to as "the
                     Licensor").
WHEREAS

(1)    The  Licensor  has applied for patents  ("the  Patents") in respect of an
invention relating to RNA Vaccines,  including HIV ("the Invention") in a number
of countries  worldwide  short  particulars of which are set forth in Schedule I
hereto.

(2)    The Licensor  has agreed to grant to the Licensee an exclusive  worldwide
licence ("the  Licence") on the terms detailed  herein to make, use exercise and
vend the Invention in all pharmaceutical forms and in all fields of application.

(3)    It is agreed that the Licence  should  supersede and replace all previous
licence agreements relating to the Invention between the parties.

NOW THIS LICENCE WITNESSETH THAT:

1.0    GRANT

1.1    The Licensor hereby grants to the Licensee an exclusive worldwide licence
to make use exercise and vend the Invention in all  pharmaceutical  forms and in
all fields of application.

1.2    The Licensor  shall not sue the Licensee  under any other patent know how
copyright registered design or other intellectual  property owned by or licensed
to the  Licensor  alone or  jointly or in common  with  others in respect of any
activity which would but for the Licence amount to infringement.

1.3    The  Licensor  owns US Patent Nos  4816250  and  5219567  relating to the
manufacture of a Herpes Vaccine which could provide protection

                                       31
<PAGE>

for the Licensees  intended  manufacture  of vaccines  under this  Licence.  The
Licensor will provide  reasonable  assistance to the Licensee,  at the Licensees
cost, in enforcing US Patent Nos 4816250 and 5219567 where the Licensee believes
that such enforcement will enable it to protect its vaccine manufacture and sale
in the USA.

ROYALTY

2.1    Upon  execution of this Licence,  the Licensee shall be obliged to pay to
the Licensor a non-refundable  payment of (pound)60,000.  (pound)10,000 shall be
payable  upon the date of  execution  of this  Licence,  (pound)20,000  shall be
payable by 30  November  1998 and the  balance  shall be payable by 31  December
1998.

2.2    For  sales in the  territories  listed  in  Schedule  I and in all  other
territories where a valid patent or similar enforceable protection (eg, pipeline
protection) with regard to the Invention  exists or becomes  available a royalty
of 5% of the net sales shall be paid to the Licensor.

2.3    For sales in countries other than those listed in Schedule I and where no
patent or similar enforceable  protection in respect of the Invention exists the
Licensee  shall pay to the  Licensor a royalty of 3% of the net sales  value per
annum.

2.4    The royalties  detailed  above in Clauses 2.2 and 2.3 shall be payable in
all countries  until the expiry of the last valid patent or similar  enforceable
protection in respect of the  Invention.  After such time the Licensee shall pay
to the  Licensor  a  royalty  of 3% of the net  sales  value  per  annum  in all
countries.  This  royalty  shall cease after a period of 10 years from the first
commercial  sale in each  country  and  thereafter  no further  royalty  will be
payable.

2.5    The Licensee shall be permitted to grant  sub-licences  to third parties,
subject to the prior approval of the Licensor,  where such approval shall not be
unreasonably withheld. The Licensee shall pay to the Licensor a 15% share of all
sub-licensee  payments in lieu of running royalty as detailed in clauses 2.2 and
2.3 3  (including  downpayments  or running  royalties).  These  payments  shall
continue until the Licensee ceases to receive payments from its sub-licensee(s).

2.6    On the I st of January  2002 and in each year  thereafter,  the  Licensee
shall pay to the  Licensor an advance  minimum  royalty of (pound)  50,000.  The
minimum  royalty shall be recoverable  from running  royalty due to the Licensor
for the same annual period.

2.7    The net sales value shall mean the Licensee's  invoice price on the first
act of sale hereunder to an independent third party after deduction of the usual
trade  discounts  and  returns  and  excluding  the costs of  packing  transport
insurance and tax.

2.8    The Licensee  shall within 30 days after the 30th June and 31st  December
in every year of the  Licence  render to the  Licensor a  statement  showing the
amount of sub-licence  income received and the net value (as defined above) on a
country by country  basis and the sum of royalties  due in respect of the period
ending on such 30th June or 3 1 st December and the  Licensee  shall at the same
time pay to the Licensor the sum due.

                                       32
<PAGE>

2.9    Royalty payments shall be made in pounds sterling subject to deduction of
any applicable  withholding  taxes but with the addition of any applicable Value
Added Tax. Net sales value shall be calculated  initially in the currency of the
country where the sales were made and if necessary  shall be converted to pounds
sterling at the midmarket spot exchange rate indicated by the Financial Times on
the final day of the period to which the royalty payment relates.

2.10   The  Licensee  shall  keep  proper  books of  account  and record and the
supporting documentation showing all matters connected with the manufacture sale
and  disposition  of its products and the amount due in respect of royalties and
shall allow the Licensor by its duly  appointed  officers or  accountants at all
reasonable  times to  inspect  and take  copies of or  extracts  from such books
records and  documentation  and any other  relevant or apparently  relevant book
account record or voucher as may be reasonably necessary for the sole purpose of
verifying the amount due in respect of royalties.  Such  inspection  may be made
notwithstanding  termination  of this  Agreement  whilst any  outstanding  claim
remains unsettled in the view of any par-ties hereto.

3.0    THE PATENTS

3.1    The Licensor shall not amend the specification of the Patents without the
p or approval  writing of the Licensee which approval shall not be  unreasonably
withheld.

3.2    Nothing  herein shall impose an  obligation on the Licensor to defend any
action or proceeding in which a claim or counter-claim is made for revocation of
any of the Patents but should the Licensor decide to defend the Patents it shall
do so at its own cost.

4.0    LICENSORS OBLIGATIONS

4.1    The Licensee  shall  reimberse the Licensor for the costs of  prosecution
and maintenance of the patents from the date of this Licence.  The Licensor will
on  demand  produce  to  the  Licensee  at  its  principal  office  the  renewal
certificate  three days at least before the last day for payment of each renewal
fee.

4.2    The Licensor  shall if and whenever  required by the Licensee  give it or
its agent and servants in confidence all such  explanations  and  information as
are now or in the future in its possession to enable the Licensee to manufacture
its products under the Licence to the best advantage.

5.0    IMPROVEMENTS

5.1    Each of the parties  hereto  shall  forthwith  on the  discovery  thereof
communicate to the other full information  concerning any improvements  relating
to the Invention and the other shall treat such information as confidential.

5.2    Any patents  existing or granted in the future to the Licensor in respect
of any application  relating to an Improvement shall be deemed to be included in
the expression  "the Patents" for the purpose of this Agreement and the Licensor
undertakes  to endorse  hereon a suitable  memorandum  of the  extension  of the
Licence to such  patents  for the  purpose of  registration  at the  appropriate
Patent Office or to execute such other document as may be necessary therefore.

                                       33
<PAGE>

5.3    Each party shall treat as  confidential  all the data  pertaining  to the
Invention  and shall not disclose any of them to any third party by  publication
or otherwise which  obligations  shall last for a period of five (5) years after
the date of execution of this agreement except:

              (a)    data  which  at the  time of  disclosure  is in the  public
                     domain;
              (b)    data  which  after  disclosure  becomes  part of the public
                     domain by publication or otherwise except by breach of this
                     Agreement by the Licensee.

6.0    INFRINGEMENT

6.1    Each of the parties hereto shall  forthwith give notice in writing to the
other party of any infringement or threatened infringement of any of the patents
which shall at any time come to its knowledge.

6.2    In the event  that there  shall be any  substantial  infringement  of the
Patents  ("substantial  infringement"  meaning  sales  by third  parties  in any
country of  products  infringing  the Patents or any of them  exceeding  in unit
terms five per  centum of the unit sales of the  Licensee  of  Products  in such
country) in any twelve month period and the Licensor does not within  forty-five
days after written notice from the Licensee of such prejudicial effect institute
proceedings  to  prevent  such  infringement  the  Licensee  may at  its  option
forthwith  so far as it  extends  to that  country  on notice in  writing to the
Licensor  institute  such  proceedings  at its own  expense  in the  name of the
Licensor giving to the Licensor an indemnity in respect of the costs of any such
proceedings and shall be entitled to retain all damages in any recovered in such
proceedings.

6.3    Payment of royalties  as from the  commencement  of any such  substantial
infringement  shall  continue so long as the  Licensee is able to sell  products
without either  reduction in price or a reduction in volume of ten per centum or
more. In the event that such reductions are necessary  royalty payments shall be
reduced in a ratio to the reductions in volume or price as the case may be.

7.0    TERMINATION

7.1    If the royalties due hereunder in respect of any half-year  have not been
paid within the time allowed or within 30 days of the due date by the Licence or
if The  Licensee  shall  commit or allow to be  committed a breach of any of the
other  covenants  promises or undertakings  herein  contained and shall not have
remedied  such breach within 60 days after notice is given to it by the Licensor
or either of them requiring such remedy or if the Licensee shall have a receiver
appointed  of the  whole  or any  part of its  asses  or any  order is made or a
resolution passed for winding up the Licensee (unless such receiver is appointed
or such order or resolution is passed as part of a scheme for  reconstruction or
amalgamation  of the  Licensee)  then the  Licensor  may  forthwith by notice in
writing  terminate the Licence without being required to give any or any further
notice in advance of such  termination but such  termination  shall 1 be without
prejudice  to the remedy of the  Licensor to sue for and  recover any  royalties
then due and to pursue any remedy in  respect of any  previous  breach of any of
the. covenants or agreement herein contained.

                                       34
<PAGE>

8.0    ANCULLARY PROVISIONS

8.1    The Licensee may have  products  manufactured  by third parties on a toll
manufacture basis provided that obligations of confidentiality  are imposed upon
the toll manufacturer.

8.2    The  Licensee  shall  carry out all  clinical  trials in  relation to its
products as may be required for registration  purposes in the various  countries
and shall pursue with due diligence  applications  for the  registration  of its
products for sale in any country where such registration is a requirement.

8.3    Any notice  required or  permitted  to be given  hereunder  may  (without
prejudice  to the use of any  other  method)  be  given by  sending  the same by
prepaid post of facsimile to the following address and contact:

For the University of Birmingham to:

University of Birmingham
Edgbaston
Birmingham
B15 2TT
UK
FAO: Mrs G Ball, Director of Finance

Tel: 0121414 6083
Fax: 0121414 6056

For Intracell Vaccines Limited to:

12 Harben Court
Collingwood,
Ontario
Canada
L9Y 4L8

FAO: Mr K W Murray

Tel: 705 444 6317

Fax:  705 444 6317

8.4    Invalidation  for  whatever  reason at  present  or due to  circumstances
somewhere in the future of any clause in the Licence or  occurrence  of a gap in
the Licence shall not have effect on the legal  effectiveness  of other clauses.
Such ineffective clause due to invalidation as mentioned above shall be replaced
or such gap as  mentioned  above  shall be  filled by an  adequately  formulated
provision which comes closest to the intentions of the  contracting  parties and
would have been properly expressed by them, had they taken such flaw or gap into
due consideration in the first place.

8.5    The Licence shall be interpreted  in all respects in accordance  with the
Laws and Courts of England.

8.6    It is agreed that the Licence  should  supersede and replace all previous
licence agreements between the parties.

                                       35
<PAGE>

SCHEDULE 1
----------

Country               Patent Application No                     Date of Filing
Application

Australia*                  637114                               12 June 1990
Canada                      2060198                              12 June 1990
Netherlands*                0477240                              12 June 1990
Germany*                    69021879.6                           12 June 1990
Italy*                      0477240                              12 June 1990
France*                     0477240                              12 June 1990
GB*                         0477240                              12 June 1990
Japan                       508641/90                            12 June 1990

* Patent granted

                                       36
<PAGE>

IN WITNESS  WHEREOF the parties  hereto have executed this Licence  Agreement on
the date and year first above written.

/s/ David T Allen
-----------------
for and on behalf of
UNIVERSITY OF BIRMINGHAM

/s/  Kevin Murray
-----------------
for and on behalf of
INTRACELL VACCINES LIMITED

                                       37AMENDMENT NO. 1 TO
                          REGISTRY MAGIC INCORPORATION
                              EMPLOYMENT AGREEMENT

         Amendment No. 1 dated July ____, 2000 to Employment Agreement dated
December 19, 1997 (the "Employment Agreement") between REGISTRY MAGIC
INCORPORATED (the "Company") and LAWRENCE COHEN (the "Executive").

         WHEREAS, the Company and the Executive have previously entered into the
Employment Agreement, and

         WHEREAS, the parties wish to extend the term of the Employment
Agreement on the terms hereafter provided:

         NOW, THEREFORE, for good and valuable consideration, the receipt and
adequacy of which are hereby acknowledged by each of the parties hereto, the
parties hereby agrees as follows:

1. The Company and the Executive agree that the term of employment of the
Employment Agreement shall be extended from December 19, 2000 through December
19, 2003.

2. For the extended term of the Agreement, the Company shall pay the Executive a
salary of $115,500 per year as provided in Section 3 of the Agreement, except
the provision relating to the increase of salary following completion of the
initial public offering of the Company shall be null and void, and the Executive
waives any right he has had with regard to such incremental salary during the
term of the Agreement.

3. Except as modified by this Amendment, the terms of the Agreement shall
continue to be in effect for the initial term of the Agreement and the extended
term as provided in this Amendment.

         IN WITNESS WHEREOF, we have executed this Amendment No. 1 to the
Agreement as of the above date.

                           REGISTRY MAGIC INCORPORATED

                                                     By:
                                                        ----------------------
                               Authorized Officer

                                                     LAWRENCE COHEN

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00044-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00044-of-00352.parquet"}]]